Literature DB >> 33727386

T S Brandon Ng1, Kori Leblanc2, Darwin F Yeung3, Teresa S M Tsang4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33727386      PMCID: PMC7963008          DOI: 10.46747/cfp.6703e69

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  84 in total

1.  [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].

Authors: 
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2020-03-12

2.  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.

Authors:  X-T Ye; Y-L Luo; S-C Xia; Q-F Sun; J-G Ding; Y Zhou; W Chen; X-F Wang; W-W Zhang; W-J Du; Z-W Ruan; L Hong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-03       Impact factor: 3.507

3.  [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].

Authors:  Y D Peng; K Meng; H Q Guan; L Leng; R R Zhu; B Y Wang; M A He; L X Cheng; K Huang; Q T Zeng
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2020-06-24

4.  Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

Authors:  Bruno M Tomazini; Israel S Maia; Alexandre B Cavalcanti; Otavio Berwanger; Regis G Rosa; Viviane C Veiga; Alvaro Avezum; Renato D Lopes; Flavia R Bueno; Maria Vitoria A O Silva; Franca P Baldassare; Eduardo L V Costa; Ricardo A B Moura; Michele O Honorato; Andre N Costa; Lucas P Damiani; Thiago Lisboa; Letícia Kawano-Dourado; Fernando G Zampieri; Guilherme B Olivato; Cassia Righy; Cristina P Amendola; Roberta M L Roepke; Daniela H M Freitas; Daniel N Forte; Flávio G R Freitas; Caio C F Fernandes; Livia M G Melro; Gedealvares F S Junior; Douglas Costa Morais; Stevin Zung; Flávia R Machado; Luciano C P Azevedo
Journal:  JAMA       Date:  2020-10-06       Impact factor: 56.272

5.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).

Authors:  Riccardo M Inciardi; Laura Lupi; Gregorio Zaccone; Leonardo Italia; Michela Raffo; Daniela Tomasoni; Dario S Cani; Manuel Cerini; Davide Farina; Emanuele Gavazzi; Roberto Maroldi; Marianna Adamo; Enrico Ammirati; Gianfranco Sinagra; Carlo M Lombardi; Marco Metra
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

6.  2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings.

Authors:  Jiangping Wei; Huaxiang Xu; Jingliang Xiong; Qinglin Shen; Bing Fan; Chenglong Ye; Wentao Dong; Fangfang Hu
Journal:  Korean J Radiol       Date:  2020-02-26       Impact factor: 3.500

7.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

8.  Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.

Authors:  J-M Michot; L Albiges; N Chaput; V Saada; F Pommeret; F Griscelli; C Balleyguier; B Besse; A Marabelle; F Netzer; M Merad; C Robert; F Barlesi; B Gachot; A Stoclin
Journal:  Ann Oncol       Date:  2020-04-02       Impact factor: 32.976

9.  Evolution of Computed Tomography Manifestations in Five Patients Who Recovered from Coronavirus Disease 2019 (COVID-19) Pneumonia.

Authors:  Qiulian Sun; Xinjian Xu; Jicheng Xie; Jingjing Li; Xiangzhong Huang
Journal:  Korean J Radiol       Date:  2020-03-13       Impact factor: 3.500

10.  Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.

Authors:  Chi Zhang; Zhao Wu; Jia-Wen Li; Hong Zhao; Gui-Qiang Wang
Journal:  Int J Antimicrob Agents       Date:  2020-03-29       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.